Linagliptin-associated bullous pemphigoid treated with rituximab.
Publication/Presentation Date
9-30-2019
Abstract
Dipeptidyl peptidase 4 (DPP-4) inhibitors are increasingly used these days in management of diabetes. There has been reported in a few case reports of increasing association between DPP-4 inhibitor use and bullous pemphigoid (BP). We report a case of association between linagliptin use and BP and subsequent treatment with rituximab.
Volume
12
Issue
9
ISSN
1757-790X
Published In/Presented At
Mani, H., Safo, P., & Onitilo, A. A. (2019). Linagliptin-associated bullous pemphigoid treated with rituximab. BMJ case reports, 12(9), e229902. https://doi.org/10.1136/bcr-2019-229902
Disciplines
Medicine and Health Sciences
PubMedID
31570343
Department(s)
Fellows and Residents
Document Type
Article
COinS